Requires hospitals to provide medically supervised detoxification services

2025 Regular Session Introduced by Steve Otis and 2 co-sponsors

Requires hospitals to provide medically supervised detoxification, improving access and safety for patients with substance use disorders; currently in Health Committee.

REFERRED TO HEALTH

Overview

A 661 is a New York Assembly bill introduced on January 8, 2025. Its primary aim is to require hospitals to provide medically supervised detoxification services. The bill is currently in the early stages of the legislative process, having been referred to the Health Committee.

Status: Referred to Health (January 8, 2025)

Introduced: January 8, 2025

Classification: Bill

Primary Sponsor: Phil Steck

Cosponsors: Steven Otis, Karines Reyes

What the bill would do

The bill would oblige hospitals to offer medically supervised detoxification services as part of their care offerings. Medically supervised detoxification typically involves clinical supervision and medical management during withdrawal from substances to ensure safety and manage withdrawal symptoms.

Specifics such as the exact standards, minimum capabilities, staffing requirements, timelines for implementation, funding, and enforcement mechanisms are not detailed in the information provided.

Key provisions and changes (as currently described)

Establishes a mandate for hospitals to provide detoxification under medical supervision.

Likely implications for hospital operations, including staffing, protocols, and coordination with broader treatment pathways (e.g., referrals to treatment after detoxification). Note: precise requirements (e.g., staffing ratios, bed capacity, reporting obligations) are not outlined in the summary available.

Who would be affected

Hospitals: Would need to ensure capacity and capability to provide medically supervised detoxification services.

Patients with substance use disorders: Could gain greater access to medically supervised withdrawal management within hospital settings.

Healthcare system and regulators: Potentially affected through compliance, reporting, and oversight responsibilities (though specific regulatory details are not provided).

Procedural and timeline aspects

The bill is currently in the Health Committee stage and has not advanced to floor action or become law.

Related legislative activity includes:

Prior-session bills: A 7376 and A 4316 (listed as related)
Senate companion: S 1987 (listed)

The presence of companion and related bills suggests ongoing interest in this policy area across sessions.

Potential impact (contextual)

Positive outcomes could include improved safety during withdrawal, increased access to detox services, and clearer pathways to subsequent treatment.

Potential challenges may involve cost, staffing, and ensuring consistent standards across diverse hospital settings.

Without the full text, exact fiscal implications, enforcement mechanisms, and implementation timelines remain to be seen.

If you’d like, I can compare A 661 to its related and companion bills (A 7376, A 4316, S 1987) once those texts are available, to highlight how the provisions differ or align across sessions and chambers.

Bill